US court ruling a blow for AstraZeneca

Tuesday 02 April 2013 21:48 BST

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

AstraZeneca swallowed some more bad news when a US court ruled that a patent protecting its Pulmicort Respules asthma medicine was invalid, clearing the way for generic competition.

Pulmicort Respules brought in US sales of $136m (£90m) last year, and a spokesman said: "AstraZeneca strongly disagrees with the court's decision [and] is considering next steps, including an appeal."

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Stay up to date with notifications from The Independent

Thank you for registering

US court ruling a blow for AstraZeneca

Join our commenting forum

Thank you for registering